Sign up
Pharma Capital

SkinBioTherapeutics 'making very good headway' in development of three key programmes

Dr Cath O'Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), caught up with Proactive's Andrew Scott following the release of the skin-health specialist's interim results.

She says they remain on track with the development of their three flagship programmes - in particular the upcoming first human study for the cosmetic application of the compound which is planned for the third quarter of this year.


View full SBTX profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.